* Stribild, a new combination anti-HIV drug, has been approved by the Food and Drug Administration. The product contains two new drugs, elvitegravir and cobicistat, and two previously approved drugs, emtricitabine and tenofovir.
* Given once daily to treatment-naïve patients with HIV-1, Stribild is considered a complete treatment for HIV. This decreases the pill burden and should aid in promoting treatment adherence.
* Stribild's label carries boxed warnings similar to the labels of some other HIV drugs.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.